Depression Treatment: Effects of the Implementation of an Evidence-Based Program to Manage Concerns About Falls in Older Adults.

Effects of the Implementation of an Evidence-Based Program to Manage Concerns About Falls in Older Adults.

Filed under: Depression Treatment

Gerontologist. 2012 Nov 6;
Zijlstra GA, van Haastregt JC, Du Moulin MF, de Jonge MC, van der Poel A, Kempen GI

Purpose of the study: Concerns about falls and related activity avoidance are common in older people. A multicomponent program reduced these concerns and increased daily activity among older people in a randomized controlled trial. This study explored whether the effects and acceptability of the program maintain after its implementation into home care organizations. DESIGN AND METHODS: In a pretest-post-test study, the effects and acceptability of the 8-week cognitive behavioral program was evaluated in 125 community-living older adults. Data on concerns about falls, related avoidance behavior, falls, fall-related medical attention, feelings of loneliness and anxiety, and symptoms of depression were collected prior to the start of the program and at 2 and 4 months. RESULTS: Pretest-post-test analyses showed significant improvements at 4 months for concerns about falls, activity avoidance, number of falls in the past 2 months, feelings of anxiety, and symptoms of depression. No significant differences were shown for daily activity, feelings of loneliness, and fall-related medical attention. IMPLICATIONS: After implementation in home care organizations, the program reduced concerns about falls, avoidance behavior, and falls in community-living older adults. These findings are highly consistent with the outcomes of a previously performed randomized controlled trial, indicating that the program can be successfully implemented in practice. Further dissemination of the program is recommended to reduce concerns about falls and related activity avoidance in community-living older people.
HubMed – depression


The paroxetine 352 bipolar trial: A study in medical ghostwriting.

Filed under: Depression Treatment

Int J Risk Saf Med. 2012 Jan 1; 24(4): 221-31
Amsterdam JD, McHenry LB

Background: The problem of ghostwriting in corporate-sponsored clinical trials is of concern to medicine, bioethics, and government agencies. We present a study of the ghostwritten archival report of an industry-sponsored trial comparing antidepressant treatments for bipolar depression: GlaxoSmithKline (GSK) paroxetine study 352. This analysis is based upon publicly available evidence presented in a complaint of research misconduct filed with the Office of Research Integrity of the Department of Health and Human Services. Objectives: We performed a deconstruction of the published study to show how primary and secondary outcome analyses were conflated, turning a ‘negative’ clinical trial into a ‘positive’ study – with conclusions and recommendations that could adversely affect patient health. Methods: The paroxetine 352 study was a randomized, double-blind, placebo-controlled, 19-site trial comparing paroxetine and imipramine in 117 patients with bipolar type I major depressive episode which was unresponsive to prior lithium carbonate therapy. Results: Analysis of the primary outcome measures found no statistically significant difference between paroxetine or imipramine versus placebo. However, the published article concluded that both drugs were efficacious versus placebo for a post hoc subgroup of patients. Conclusions: Few industry-sponsored studies gain public scrutiny. It is important to make these articles transparent to the scientific and medical community.
HubMed – depression


Patterns of symptom reporting during pregnancy comparing opioid maintained and control women.

Filed under: Depression Treatment

J Addict Med. 2012 Dec; 6(4): 258-64
Gordon AL, Lopatko OV, Stacey H, Pearson V, Woods A, Fisk A, White JM

: To characterize the range of symptoms experienced by pregnant methadone-maintained (MM) and buprenorphine-maintained (BM) women to determine whether these differ from those experienced by a control group of nonopioid exposed pregnant women. Opioid-maintained (OM) patients report high rates of symptoms related to direct opioid effects and withdrawal. Pregnancy is associated with a range of symptoms, some overlapping with opioid effects and withdrawal.: Prospective, nonrandomized, open-label comparison study undertaken in a large teaching maternity hospital in South Australia. Pregnant BM (n = 25), MM (n = 25) and nonopioid exposed controls (n = 25) were recruited and matched for age, parity, gravidity, alcohol consumption, and smoking status. Symptom report patterns, maternal withdrawal, and additional substance use were assessed.: MM women reported 10 and BM women reported 2 symptoms throughout pregnancy at rates greater than controls. Methadone-maintained women reported significantly (P < 0.05) more symptoms than BM women compared to controls throughout pregnancy. Methadone-maintained women reported 8 and BM women reported 3 symptoms in the third trimester at rates greater than controls. Methadone-maintained women reported greater opioid withdrawal than controls; this did not occur in BM women. Additional substance use was comparable between BM and MM women but greater than controls.: Patterns of symptom reports may have clinical implications for maternal and fetal health during pregnancy for OM women including optimization of opioid dosing regimens, education regarding maternal nutritional intake and preventing postnatal depression, thereby ensuring maternal health and fetal development during pregnancy and enhancing mother-infant bonding and healthy child development postnatally. HubMed – depression


Depression: Treatment Strategies and Management (Medical Psychiatry Series)
Guiding clinicians toward the most effective treatment regimens, this reference offers detailed coverage of the symptomatology, di…

Amoryn – Depression & Anxiety
AMORYN works by increasing the levels of all four of the brain’s “feel good” neurotransmitters. By providing an all-natural boost …

Midwest Center! Lucinda Basset, Attacking Stress, Anxiety and Depression! Master Kit, 2008 Edition!
Attacking Stress Anxiety & Depression The Midwest Center Master Kit! 2008 Edition Product Reatails for over 500 Dollars! Get it he…

Related Depression Treatment Information…